Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus

Journal of Pharmaceutical Sciences

Volumn 99, Issue 1, 2010, Pages 524-538

  Nestorov, I ^a   Papasouliotis, O ^b   Rossi, C Pena ^b   Munafo, A ^b  

^a ZYMOGENETICS INC   (United States)

^b MERCK SERONO S A   (Switzerland)

Author keywords

APRIL; Atacicept; Bioavailability; BLyS; Dose response dose proportionality; Nonlinear pharmacokinetics; Pharmacokinetics; Systemic lupus erythematosus

Indexed keywords

ATACICEPT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO;

ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 73949102012     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21839     Document Type: Article

References (20)

1. Pugh-Bernard AE, Cambier JC. 2006. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 18:4510-4515.
2. Dillon SR, Gross JA, Ansell SM, Novak AJ. 2006. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5:235-246.
3. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. 1999. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260-263.
4. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-1756.
5. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-999.
6. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-1710.
7. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. 2001. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10.
8. Cheema GS, Roschke V, Hilbert DM, Stohl W. 2001. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313-1319.
9. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. 2005. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 64:1065-1067.
10. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. 2002. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immunebased rheumatic diseases. J Immunol 169:4314-4321.
11. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. 2003. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48:982-992.
12. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109:59-68.
13. Browning JL. 2006. B cells move to centre stage: Novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564-576.
14. Munafo A, Priestley A, Nestorov I, Visich J, Rogge M. 2007. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharm 63:647-656.
15. Tak P, Thurlings R, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. 2008. Atacicept in patients with rheumatoid arthritis: An exploratory, multicenter, double-blind, placebo-controlled, dose-escalating, single and repeat dose Phase Ib study. Arthritis Rheum 58:61-72.
16. Nestorov I, Munafo A, Papasouliotis O, Visich J. 2008. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 48:406-417.
17. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. 2007. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:4142-4150.
18. Pena Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, et al. 2009. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18:547-555.
19. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JCW. 2006. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54:723-732.
20. Porter CJH, Charman SA. 2000. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89:297-310.